We are collaborating with leading hospitals, integrated health systems, medical centers and biobanks around the world to conduct studies in order to further develop and validate UDX's blood test for early cancer detection.
+140
CLINICAL INSTITUTIONS
10
Countries
+14k
subjects RECRUITED
6
Studies
Signal-C® has initiated its clinical validation study in accordance with FDA requirements, with more than 15,000 patients. This validation study is expected to be completed by the mid 2025 . More information at ClinicalTrials.gov